HRTX Heron Therapeutics, Inc.: Earnings per share for the last 12 months

Heron Therapeutics Inc (HRTX) - corporate logo

Heron Therapeutics (HRTX) is a pharmaceutical business developing oncology and pain management treatments that expands its product portfolio through patents without significantly increasing headcount. The company relies on third-party manufacturers, increasing deliveries to clinics to reduce unit promotion costs. This price chart shows EPS TTM at -46.50, as the firm competes for the hospital market by demonstrating the efficacy of its solutions.

Heron Therapeutics Inc (HRTX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

HRTX (Heron Therapeutics Inc): analytical breakdowns and indicator data

Fundamental company valuation:HRTX Heron Therapeutics
Flagship merchandise of Heron

This indicator calculates the percentage change in earnings per share over a rolling year, neutralizing seasonal reporting fluctuations. The metric reveals the actual balance between fundamental business growth and market speculation. For Heron Therapeutics (HRTX), which utilizes outsourced manufacturing, this calculation reflects cost management efficiency with minimal internal assets. By analyzing the rolling annual EPS change, an investor can distinguish a genuine trend reversal from random market noise.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months